Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU).

Pfizer Inc. announced today that the PROFILE 1007 study demonstrated that XALKORI ( crizotinib ) significantly improved progression-free survival ( PFS ) when compared with pemetrexed or docetaxel , in previously treated patients with anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer ( NSCLC ).